

## **Clovis Oncology Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 08-Oct-2012

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# Clovis Oncology Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Clovis Oncology Inc
<b>Parent Company Name</b>	Clovis Oncology Inc
<b>Website</b>	<a href="http://www.clovisoncology.com/">http://www.clovisoncology.com/</a>
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	5
<b>Number of Inactive Drugs</b>	1
<b>Number of Patents as Owner</b>	4
<b>Number of Patents as Third Party</b>	1
<b>Number of Deals</b>	7
<b>Key Indications</b>	Non-small-cell lung cancer,Breast tumor,Ovary tumor,Pancreas tumor,Melanoma,Gastrointestinal stromal tumor,Solid tumor,Cancer,Metastasis,Prostate tumor
<b>Key Target-based Actions</b>	KIT gene inhibitor,Equilibrative nucleoside transporter 1 modulator,VEGF ligand inhibitor
<b>Key Technologies</b>	Oral formulation,Small molecule therapeutic,Drug combination,Formulation preservation,Monoclonal antibody humanized,Parenteral formulation

## COMPANY PROFILE

### SUMMARY

Clovis Oncology, founded in May 2009 by former Pharmion executives, in-licenses cancer drugs at all stages of clinical development.

### LOCATION

Clovis is headquartered in Boulder, CO, and has additional offices in San Francisco, CA and Cambridge, UK.

### FINANCIAL

In March 2012, Clovis filed a registration statement on Form S-1 with the US SEC for an underwritten public offering of its \$75 million common stock shares. Underwriters were to be granted an option to purchase up to \$11.25 million of additional shares to cover over-allotments; in April 2012, the company offered the underwritten public offering of 3.75 million shares priced at \$20 per share and additional 562,500 shares were granted to the underwriters. The offering was expected to close on April 10, 2012.

In November 2011, the company priced its initial public offering of 10 million shares of its common stock at \$13 per share. At that time, the company also granted the underwriters a 30-day overallotment option to buy an additional 1.5 million shares of its common stock. Clovis's shares would trade on the NASDAQ Global Select Market under the ticker symbol 'CLVS' from November 16, 2011, and the offering was expected to close on November 21, 2011. Later in November 2011, underwriters exercised their overallotment option to purchase an additional 0.7 million shares.

In May 2009, Clovis raised \$145 million in start-up financing


[Return to Table of Contents](#)

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


Indication	Active	Inactive	Total
Neoplasm	5	1	6
Gastrointestinal disease	2	1	3
Gynecology and obstetrics	2	0	2
Genitourinary disease	2	0	2
Respiratory disease	2	0	2
Endocrine disease	2	0	2

[Return to Table of Contents](#)

Dermatological disease	1	0	1
------------------------	---	---	---

### Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	4
Discovery	1
Discontinued	1

### DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	1	0	0	0	1
Technology - Other Proprietary	0	0	3	0	3
Drug - Development/Commercialization License	0	0	3	0	3

[Return to Table of Contents](#)



## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	4	8
Gastrointestinal disease	1	3
Respiratory disease	2	2
Gynecology and obstetrics	0	1
Genitourinary disease	0	1
Endocrine disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	3
Phase 1	3	4
Phase not specified	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Immune disorder	2	0	2
Neoplasm	4	1	5
Metabolic disorder	1	0	1
Neurological disease	1	0	1
Andrology	2	0	2
Cardiovascular disease	1	0	1
Endocrine disease	2	1	3
Genitourinary disease	2	0	2

[Return to Table of Contents](#)



Dermatological disease	2	0	2
Gastrointestinal disease	3	0	3
Hematological disease	2	0	2
Respiratory disease	2	0	2
Injury	1	0	1
Gynecology and obstetrics	1	1	2

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology

<b>Drug Name</b>	gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology
<b>Key Synonyms</b>	gemcitabine elaidate
<b>Originator Company</b>	Clavis Pharma ASA
<b>Active Companies</b>	Clovis Oncology Inc
<b>Inactive Companies</b>	Clavis Pharma ASA
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Pancreas tumor, Non-small-cell lung cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	DNA synthesis inhibitor, Anticancer antimetabolite
<b>Technologies</b>	Prodrug, Lipid, Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	24-Aug-2012

### rucaparib phosphate (iv, solid tumors), Clovis

<b>Drug Name</b>	rucaparib phosphate (iv, solid tumors), Clovis
<b>Key Synonyms</b>	rucaparib phosphate, rucaparib
<b>Originator Company</b>	The University of Newcastle Upon Tyne
<b>Active Companies</b>	Clovis Oncology Inc
<b>Inactive Companies</b>	Pfizer Inc, The University of Newcastle Upon Tyne, Cancer Research Campaign Technology Ltd, Agouron Pharmaceuticals Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Breast tumor, Melanoma, Ovary tumor
<b>Target-based Actions</b>	PARP inhibitor
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	18-Sep-2012

[Return to Table of Contents](#)



**CO-1686**

<b>Drug Name</b>	CO-1686
<b>Key Synonyms</b>	
<b>Originator Company</b>	Avila Therapeutics Inc
<b>Active Companies</b>	Celgene Corp, Clovis Oncology Inc
<b>Inactive Companies</b>	Avila Therapeutics Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-small-cell lung cancer
<b>Target-based Actions</b>	EGFR family tyrosine kinase receptor inhibitor
<b>Other Actions</b>	Apoptosis stimulator, Anticancer protein kinase inhibitor
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	09-Aug-2012

**rucaparib phosphate (oral, solid tumors), Clovis**

<b>Drug Name</b>	rucaparib phosphate (oral, solid tumors), Clovis
<b>Key Synonyms</b>	rucaparib phosphate
<b>Originator Company</b>	The University of Newcastle Upon Tyne
<b>Active Companies</b>	Clovis Oncology Inc
<b>Inactive Companies</b>	Pfizer Inc, The University of Newcastle Upon Tyne, Agouron Pharmaceuticals Inc, Cancer Research Technology Ltd
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Breast tumor, Solid tumor, Ovary tumor
<b>Target-based Actions</b>	PARP inhibitor
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Oral formulation, Tablet formulation, Small molecule therapeutic
<b>Last Change Date</b>	18-Sep-2012

[Return to Table of Contents](#)


KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology

Drug Name	KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology
Key Synonyms	
Originator Company	Clovis Oncology Inc
Active Companies	Clovis Oncology Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Gastrointestinal stromal tumor
Target-based Actions	KIT gene inhibitor
Other Actions	Anticancer
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	17-Jul-2012

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

